| Identification | Back Directory | [Name]
3-(5-BroMo-1-Methyl-1H-indol-3-yl)-4-(benzofuran-3-yl)pyrrole-2,5-dione | [CAS]
941575-71-9 | [Synonyms]
BIP-135
3-(5-BroMo-1-Methyl-1H-indol-3-yl)-4-(benzofuran-3-yl)pyrrole-2,5-dione
3-(Benzofuran-3-yl)-4-(5-bromo-1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione | [Molecular Formula]
C21H13BrN2O3 | [MDL Number]
MFCD16495779 | [MOL File]
941575-71-9.mol | [Molecular Weight]
421.244 |
| Chemical Properties | Back Directory | [Boiling point ]
643.5±55.0 °C(Predicted) | [density ]
1?+-.0.1 g/cm3(Predicted) | [storage temp. ]
room temp | [solubility ]
DMSO: ≥15mg/mL | [form ]
powder | [pka]
7.44±0.60(Predicted) | [color ]
light orange to dark orange |
| Hazard Information | Back Directory | [Uses]
Acts as a potent GSK-3 inhibitor which leads to therapeutic treatment of spinal muscular atrophy. | [in vivo]
BIP-135 does not appear to be toxic and was well-tolerated by the animals (no decrease in body weight)[1].
BIP-135 (75 mg/kg; i.p.; daily; from postnatal day 0 to 21) prolongs the median survival time of Δ7 SMA KO mouse model of spinal muscular atrophy[1].
| Animal Model: | Male and female SMN2+/+, SMN2Δ7+/+, Smn+/– mice[1] | | Dosage: | 75 mg/kg | | Administration: | Intraperitoneal injection; daily; from postnatal day 0 to 21 | | Result: | Caused a modest extension in the median survival of SMA KO animals by two days. |
| [IC 50]
GSK-3α: 16 nM (IC50); GSK-3β: 21 nM (IC50) |
|
|